Drug Profile
Research programme: cancer pain therapeutics - Benitec
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Benitec Ltd
- Developer Benitec Biopharma
- Class Small interfering RNA
- Mechanism of Action D amino acid oxidase inhibitors; Gene silencing; Protein kinase C gamma inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer-pain in Australia (Intrathecal, Injection)
- 18 May 2011 Preclinical trials in Cancer pain in Australia (Intrathecal)